tiprankstipranks
Reviva Pharmaceuticals Secures European Patent for Brilaroxazine
Company Announcements

Reviva Pharmaceuticals Secures European Patent for Brilaroxazine

Don't Miss Our New Year's Offers:

An announcement from Reviva Pharmaceuticals Holdings (RVPH) is now available.

Reviva Pharmaceuticals Holdings, Inc. has announced the issuance of a European patent for their drug brilaroxazine for treating pulmonary hypertension, expanding their intellectual property portfolio across major markets including the US, China, and Japan. The patent encompasses treatment for all pulmonary hypertension patients and specifically for those with chronic obstructive pulmonary disease or sickle cell disease. Additionally, brilaroxazine has been recognized with Orphan Drug Designation in the US for pulmonary arterial hypertension.

For a thorough assessment of RVPH stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskReviva Pharmaceuticals Strengthens Financial Position with Offering
TheFlyReviva Pharmaceuticals 12M share Spot Secondary priced at $1.50
TheFlyReviva Pharmaceuticals announces common stock, warrant offering, no amount given
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App